<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920098</url>
  </required_header>
  <id_info>
    <org_study_id>1190532</org_study_id>
    <nct_id>NCT03920098</nct_id>
  </id_info>
  <brief_title>Association Between Maternal Metabolic Disturbances During the First Pregnancy and Breast Density</brief_title>
  <official_title>Association Between Maternal Metabolic Disturbances During the First Pregnancy and Breast Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Nutrición y Tecnología de los Alimentos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio de Salud Metropolitano Sur Oriente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Nutrición y Tecnología de los Alimentos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background. Breast cancer (BC) is the leading cause of cancer-related mortality in Chilean
      women. Mammographic density (BD) refers to the percentage of dense tissue of an entire
      breast. A high BD is the strongest known risk factor for BC. BD is partially modifiable; the
      first full term pregnancy (FFTP) reduces BD by average 12%. However, half of the women have
      no changes in BD after their FFTP and there is no evidence about factors that influence this
      lack of reduction. Identifying women who do not reduce BD after their FFTP and the potential
      factors associated with this lack of reduction would help to recognize a subgroup of women
      with greater vulnerability to BC. In some women, such as obese pregnant women of women with
      gestational diabetes (GDM), the metabolic adaptations are exaggerated and they show a
      disturbed metabolic milieu (characterized by hyperinsulinemia, hyperglycemia, higher
      C-reactive protein levels, and lower level of sex hormone-binding globulin), which may have
      biological effects on breast composition during this period of breast differentiation.
      Hypothesis. The hypothesis of the study proposes that the women with an altered metabolic
      milieu during their first full-term pregnancy will have higher breast density measured
      through DXA three months after cessation of lactation, when fully breast involution after
      pregnancy is achieved, compared to women without metabolic disturbances during their first
      full-term pregnancy. General Objective. The main goal is to evaluate in a cohort of primipara
      women the association between an altered metabolic milieu during pregnancy and breast density
      measured by DXA three months after breastfeeding cessation. Methods. One thousand pregnant
      women will be recruited at the beginning of their first pregnancy and evaluated at &lt;15, 24-38
      and 35-37 weeks during pregnancy and three months after breastfeeding cessation, as part of a
      longitudinal study. The main outcome will be breast composition measures three months after
      breastfeeding cessation. The main predictor will be metabolic status during pregnancy. Three
      months after breastfeeding cessation will record delivery data and a breast DXA exam will be
      carried out. Multiple linear regression models and generalized estimated equations will be
      used to explain this relationship. Expected results. The ultimate goal is to provide evidence
      on how to prevent breast cancer risk by reducing breast density.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breast absolute fibro-glandular volume (AFGV) measured by DXA technique</measure>
    <time_frame>Three months after breastfeeding cessation</time_frame>
    <description>cm3 and tertiles of their distribution estimated by DXA technique</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breast percentage of fibro-glandular volume (%FVG) measured by DXA technique</measure>
    <time_frame>Three months after breastfeeding cessation</time_frame>
    <description>percentage and tertiles of their distribution estimated by DXA technique</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Density</condition>
  <arm_group>
    <arm_group_label>Primipara pregnant women</arm_group_label>
    <description>Primipara pregnant women</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Altered metabolic milieu during first full term pregnancy</intervention_name>
    <description>The altered metabolic milieu is defined as a fasting glucose level &gt;100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels &gt; 92 mg/dL and/or plasma glucose levels &gt; 153 mg/dL two hours afterload in the oral glucose tolerance test according to ADA guidelines or a fasting glucose &gt;100 mg/dL and/or &gt; 140 mg/dL two hours afterload in the oral glucose tolerance test according to national guidelines.</description>
    <arm_group_label>Primipara pregnant women</arm_group_label>
    <other_name>Altered metabolic milieu</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Additional fasting venous samples will be collected during routine public health care blood
      extractions. Plasma and red blood cells will be separated by centrifugation within the next 3
      hours in the County´s laboratory. Red blood cells will be eliminated and plasma specimens
      will be aliquot and keep to -80ºC until the determination of metabolic markers, growth
      factors and hormones.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population is women seeking prenatal care in any of 12 public health care centers
        (PHCC) of Puente Alto and La Florida counties. Puente Alto and La Florida are low- and
        middle-income levels counties located in the city of Santiago, Chile.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primipara (no previous pregnancies)

          -  18 to 25 years of age

          -  Gestation &lt;15 weeks at first prenatal visit

          -  No intention to move outside the city of Santiago in the next to years

        Exclusion Criteria:

          -  Multipara

          -  Pre-existing cancer (except non-melanoma skin cancer)

          -  Family history of breast cancer (one first-degree female relative diagnosed with
             breast cancer)

          -  High-risk pregnancy according to national guidelines

          -  During the follow-up, pregnant women under any treatment that may affect the levels of
             metabolic markers will be excluded from the analysis

          -  Pregnant women with pre-eclampsia or with preterm birth (less than 37 weeks of
             gestational age) will be also excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Primipara pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María L Garmendia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Nutrición y Tecnología de Alimentos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María L Garmendia, PhD</last_name>
    <phone>56229781402</phone>
    <email>mgarmendia@inta.uchile.cl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Corporación de Salud Municipal de Puente Alto</name>
      <address>
        <city>Santiago de Chile</city>
        <state>Puente Alto</state>
        <zip>8210269</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Flores, MSc</last_name>
      <phone>+56948545449</phone>
      <email>marcela.flores@cmpuentealto.cl</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69.</citation>
    <PMID>16775176</PMID>
  </reference>
  <reference>
    <citation>Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007 Jan 18;356(3):227-36.</citation>
    <PMID>17229950</PMID>
  </reference>
  <reference>
    <citation>Boyd N, Berman H, Zhu J, Martin LJ, Yaffe MJ, Chavez S, Stanisz G, Hislop G, Chiarelli AM, Minkin S, Paterson AD. The origins of breast cancer associated with mammographic density: a testable biological hypothesis. Breast Cancer Res. 2018 Mar 7;20(1):17. doi: 10.1186/s13058-018-0941-y.</citation>
    <PMID>29514672</PMID>
  </reference>
  <reference>
    <citation>Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):343-9.</citation>
    <PMID>15734956</PMID>
  </reference>
  <reference>
    <citation>Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, Hopper JL. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002 Sep 19;347(12):886-94.</citation>
    <PMID>12239257</PMID>
  </reference>
  <reference>
    <citation>Varghese JS, Thompson DJ, Michailidou K, Lindström S, Turnbull C, Brown J, Leyland J, Warren RM, Luben RN, Loos RJ, Wareham NJ, Rommens J, Paterson AD, Martin LJ, Vachon CM, Scott CG, Atkinson EJ, Couch FJ, Apicella C, Southey MC, Stone J, Li J, Eriksson L, Czene K, Boyd NF, Hall P, Hopper JL, Tamimi RM; MODE Consortium, Rahman N, Easton DF. Mammographic breast density and breast cancer: evidence of a shared genetic basis. Cancer Res. 2012 Mar 15;72(6):1478-84. doi: 10.1158/0008-5472.CAN-11-3295. Epub 2012 Jan 19.</citation>
    <PMID>22266113</PMID>
  </reference>
  <reference>
    <citation>Nazari SS, Mukherjee P. An overview of mammographic density and its association with breast cancer. Breast Cancer. 2018 May;25(3):259-267. doi: 10.1007/s12282-018-0857-5. Epub 2018 Apr 12. Review.</citation>
    <PMID>29651637</PMID>
  </reference>
  <reference>
    <citation>Rice MS, Rosner BA, Tamimi RM. Percent mammographic density prediction: development of a model in the nurses' health studies. Cancer Causes Control. 2017 Jul;28(7):677-684. doi: 10.1007/s10552-017-0898-7. Epub 2017 May 6.</citation>
    <PMID>28478536</PMID>
  </reference>
  <reference>
    <citation>Yaghjyan L, Colditz GA, Rosner B, Bertrand KA, Tamimi RM. Reproductive factors related to childbearing and mammographic breast density. Breast Cancer Res Treat. 2016 Jul;158(2):351-9. doi: 10.1007/s10549-016-3884-y. Epub 2016 Jun 28.</citation>
    <PMID>27351801</PMID>
  </reference>
  <reference>
    <citation>Rice MS, Bertrand KA, Lajous M, Tamimi RM, Torres G, López-Ridaura R, Romieu I. Reproductive and lifestyle risk factors and mammographic density in Mexican women. Ann Epidemiol. 2015 Nov;25(11):868-73. doi: 10.1016/j.annepidem.2015.08.006. Epub 2015 Aug 29.</citation>
    <PMID>26475982</PMID>
  </reference>
  <reference>
    <citation>Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002 Jul 20;360(9328):187-95.</citation>
    <PMID>12133652</PMID>
  </reference>
  <reference>
    <citation>Gabrielson M, Chiesa F, Behmer C, Rönnow K, Czene K, Hall P. Association of reproductive history with breast tissue characteristics and receptor status in the normal breast. Breast Cancer Res Treat. 2018 Aug;170(3):487-497. doi: 10.1007/s10549-018-4768-0. Epub 2018 Mar 30.</citation>
    <PMID>29603032</PMID>
  </reference>
  <reference>
    <citation>Britt K, Ashworth A, Smalley M. Pregnancy and the risk of breast cancer. Endocr Relat Cancer. 2007 Dec;14(4):907-33. Review.</citation>
    <PMID>18045947</PMID>
  </reference>
  <reference>
    <citation>Vashi R, Hooley R, Butler R, Geisel J, Philpotts L. Breast imaging of the pregnant and lactating patient: imaging modalities and pregnancy-associated breast cancer. AJR Am J Roentgenol. 2013 Feb;200(2):321-8. doi: 10.2214/AJR.12.9814. Review.</citation>
    <PMID>23345353</PMID>
  </reference>
  <reference>
    <citation>Sabate JM, Clotet M, Torrubia S, Gomez A, Guerrero R, de las Heras P, Lerma E. Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics. 2007 Oct;27 Suppl 1:S101-24. doi: 10.1148/rg.27si075505. Review.</citation>
    <PMID>18180221</PMID>
  </reference>
  <reference>
    <citation>Loehberg CR, Heusinger K, Jud SM, Haeberle L, Hein A, Rauh C, Bani MR, Lux MP, Schrauder MG, Bayer CM, Helbig C, Grolik R, Adamietz B, Schulz-Wendtland R, Beckmann MW, Fasching PA. Assessment of mammographic density before and after first full-term pregnancy. Eur J Cancer Prev. 2010 Nov;19(6):405-12. doi: 10.1097/CEJ.0b013e32833ca1f4.</citation>
    <PMID>20700056</PMID>
  </reference>
  <reference>
    <citation>Strange KS, Wilkinson D, Edin G, Emerman JT. Mitogenic properties of insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and epidermal growth factor on human breast stromal cells in primary culture. Breast Cancer Res Treat. 2004 Mar;84(2):77-84.</citation>
    <PMID>14999138</PMID>
  </reference>
  <reference>
    <citation>Rosato V, Bosetti C, Talamini R, Levi F, Montella M, Giacosa A, Negri E, La Vecchia C. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol. 2011 Dec;22(12):2687-2692. doi: 10.1093/annonc/mdr025. Epub 2011 Mar 17.</citation>
    <PMID>21415236</PMID>
  </reference>
  <reference>
    <citation>Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, Krogh V. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis. 2010 Jan;20(1):41-8. doi: 10.1016/j.numecd.2009.02.006. Epub 2009 Apr 10.</citation>
    <PMID>19361966</PMID>
  </reference>
  <reference>
    <citation>Buschard K, Thomassen K, Lynge E, Vejborg I, Tjønneland A, von Euler-Chelpin M, Andersen ZJ. Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort. Cancer Causes Control. 2017 Jan;28(1):13-21. doi: 10.1007/s10552-016-0829-z. Epub 2016 Nov 10.</citation>
    <PMID>27832382</PMID>
  </reference>
  <reference>
    <citation>Pereira A, Garmendia ML, Uauy R, Neira P, Lopez-Arana S, Malkov S, Shepherd J. Determinants of volumetric breast density in Chilean premenopausal women. Breast Cancer Res Treat. 2017 Apr;162(2):343-352. doi: 10.1007/s10549-017-4126-7. Epub 2017 Jan 28.</citation>
    <PMID>28132392</PMID>
  </reference>
  <reference>
    <citation>Chen YH, Ferguson KK, Meeker JD, McElrath TF, Mukherjee B. Statistical methods for modeling repeated measures of maternal environmental exposure biomarkers during pregnancy in association with preterm birth. Environ Health. 2015 Jan 26;14:9. doi: 10.1186/1476-069X-14-9.</citation>
    <PMID>25619201</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Nutrición y Tecnología de los Alimentos</investigator_affiliation>
    <investigator_full_name>Dr. Maria Luisa Garmendia</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Breast densities</keyword>
  <keyword>Breast neoplasms</keyword>
  <keyword>Glucose metabolism disorders</keyword>
  <keyword>Diabetes, gestational</keyword>
  <keyword>Glycated Hemoglobin A</keyword>
  <keyword>Insulin-Like Growth Factor I</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Gestation</keyword>
  <keyword>Primary Health Care</keyword>
  <keyword>Dual-energy X-ray Absorptiometry</keyword>
  <keyword>Latin America</keyword>
  <keyword>Chile</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

